AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20951321 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (intravenous hydrocortisone 2 mg/kg on the day of procedure and oral prednisolone 0.5 mg/kg/day for 3 days after PVI)
Number of subjects: 125
Study 20951321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 20951321 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 125
Study 17692385 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 72
Study 17692385 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 15452804 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment starting at 3 weeks post-surgery
Number of subjects: 27
Study 15452804 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment starting at 6 weeks post-surgery
Number of subjects: 27
Study 15452804 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment starting at 1 week post-surgery
Number of subjects: 27
Study 15452804 — intervention group
Group type: COMPARATOR
Intervention: No steroid treatment (NST)
Number of subjects: 27
Study 11420164 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon counterpulsation therapy (IABP)
Number of subjects: 0
Study 9679847 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 343
Study 9679847 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 100 mg once daily
Number of subjects: 343
Study 9679847 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 200 mg once daily
Number of subjects: 343
Study 9679847 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg twice daily
Number of subjects: 343
Study 9679847 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 50 mg twice daily
Number of subjects: 343
Study 9679847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 7862791 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult Form of Coopersmith's Self‐esteem Inventory
Number of subjects: 90
Study 7862791 — intervention group
Group type: EXPERIMENTAL
Intervention: TestWell (revised wellness inventory)
Number of subjects: 90
Study 2492252 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy
Number of subjects: 50
Study 2492252 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin + nitroglycerin
Number of subjects: 50
Study 2492252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 50
Study 16324164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol/APAP (75 mg/650 mg)
Number of subjects: 305
Study 16324164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 30052579 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating Challenge (HC)
Number of subjects: 59
Study 30052579 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Pc-aCO2 >17 mm Hg with positive ΔPcCO2
Number of subjects: 59
Study 29141365 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting combined oral contraceptives
Number of subjects: 726
Study 24621661 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention programme (Group A)
Number of subjects: 204
Study 24621661 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention (Group B)
Number of subjects: 204
Study 24621661 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 204
Study 23789934 — intervention group
Group type: EXPERIMENTAL
Intervention: Raisins
Number of subjects: 26
Study 23789934 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapes
Number of subjects: 26
Study 23789934 — intervention group
Group type: COMPARATOR
Intervention: Potato Chips
Number of subjects: 26
Study 23789934 — intervention group
Group type: COMPARATOR
Intervention: Cookies
Number of subjects: 26
Study 22117718 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite (G1) for 1 min
Number of subjects: 86
Study 22117718 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite (G1) for 10 min
Number of subjects: 86
Study 22117718 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate (G2) for 1 min
Number of subjects: 86
Study 22117718 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate (G2) for 10 min
Number of subjects: 86
Study 22117718 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine (G3) for 1 min
Number of subjects: 86
Study 22117718 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine (G3) for 10 min
Number of subjects: 86
Study 22117718 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (G4) for 1 min
Number of subjects: 86
Study 22117718 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (G4) for 10 min
Number of subjects: 86
Study 18608543 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet C (increased consumption of breakfast cereals)
Number of subjects: 57
Study 18608543 — intervention group
Group type: COMPARATOR
Intervention: Diet V (increased consumption of vegetables)
Number of subjects: 57
Study 18608543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Diet C and Diet V
Number of subjects: 57
Study 18608543 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet C
Number of subjects: 57
Study 16783667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (B) alone
Number of subjects: 45
Study 16783667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (B) + 10 mg Fentanyl (F)
Number of subjects: 45
Study 16783667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (B) + 20 mg Fentanyl (F)
Number of subjects: 45
Study 16783667 — intervention group
Group type: COMPARATOR
Intervention: Control group (Bupivacaine alone)
Number of subjects: 45
Study 15156797 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unilateral neglect
Number of subjects: 0
Study 11305405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin at 24 to 70 mg/kg/day
Number of subjects: 237
Study 11305405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin for simple partial seizures
Number of subjects: 237
Study 11305405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin for complex partial seizures
Number of subjects: 237
Study 11305405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin for secondarily generalized tonic-clonic seizures
Number of subjects: 237
Study 11305405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 237
Study 9253313 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-testosterone administered to boys
Number of subjects: 49
Study 9253313 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens administered to girls
Number of subjects: 49
Study 9253313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 8494650 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of almagate (1.5 g, po)
Number of subjects: 21
Study 8494650 — intervention group
Group type: COMPARATOR
Intervention: Alginate + antacid (2.4 g, po)
Number of subjects: 21
Study 3661479 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily aerobic exercise
Number of subjects: 8
Study 3661479 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 8
Study 29951552 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive derived from natural latex associated with a light‐emitting diode (LED) circuit (group 1)
Number of subjects: 15
Study 29951552 — intervention group
Group type: COMPARATOR
Intervention: Dressing at home performed by nurses (group 2)
Number of subjects: 15
Study 29951552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing adhesive derived from natural latex associated with the LED circuit (group 3)
Number of subjects: 15
Study 27009893 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 2525
Study 27009893 — intervention group
Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 2525
Study 24931249 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 120
Study 24931249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 120
Study 24931249 — intervention group
Group type: COMPARATOR
Intervention: Swimming
Number of subjects: 120
Study 24931249 — intervention group
Group type: COMPARATOR
Intervention: Powerstriding
Number of subjects: 120
Study 24931249 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 22430689 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA followed by 3% NaOCl as root canal irrigant (Group A)
Number of subjects: 60
Study 22430689 — intervention group
Group type: EXPERIMENTAL
Intervention: MTAD as root canal irrigant (Group B)
Number of subjects: 60
Study 22430689 — intervention group
Group type: COMPARATOR
Intervention: Saline as root canal irrigant (Control Group)
Number of subjects: 60
Study 20660429 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (negative viscosity + inertia)
Number of subjects: 0
Study 20660429 — intervention group
Group type: COMPARATOR
Intervention: Inertia training
Number of subjects: 0
Study 18851776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Number of subjects: 269
Study 18851776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 100 mg
Number of subjects: 269
Study 18851776 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone HCl IR 10 mg
Number of subjects: 269
Study 18851776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 14699540 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid for 5 days postoperatively
Number of subjects: 288
Study 14699540 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin postoperatively
Number of subjects: 288
Study 14699540 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 288
Study 11735775 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion therapy
Number of subjects: 0
Study 11735775 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 9643210 — intervention group
Group type: EXPERIMENTAL
Intervention: Endekay (urea) chewing gum
Number of subjects: 20
Study 9643210 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride chewing gum
Number of subjects: 20
Study 9643210 — intervention group
Group type: EXPERIMENTAL
Intervention: Trident chewing gum
Number of subjects: 20
Study 9643210 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrigley's chewing gum
Number of subjects: 20
Study 9643210 — intervention group
Group type: COMPARATOR
Intervention: Sucrose 10% (w/v) rinse (control)
Number of subjects: 20
Study 8424267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8424267 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 U of rHuEPO per kg
Number of subjects: 50
Study 8424267 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 U of rHuEPO per kg
Number of subjects: 50
Study 3818750 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixator
Number of subjects: 58
Study 3818750 — intervention group
Group type: COMPARATOR
Intervention: Forearm plaster
Number of subjects: 58
Study 30987814 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine solution for meatal cleaning before urinary catheterization
Number of subjects: 1642
Study 30987814 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (control phase)
Number of subjects: 1642
Study 30383074 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive self-ligating brackets (Damon System)
Number of subjects: 24
Study 30383074 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets (Roth philosophy)
Number of subjects: 24
Study 26704029 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 4177
Study 26704029 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 4177
Study 24149007 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure lowering
Number of subjects: 2582
Study 24149007 — intervention group
Group type: COMPARATOR
Intervention: Guideline‐recommended blood pressure lowering
Number of subjects: 2582
Study 22692171 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin and meropenem (1 g every 8 hours of meropenem and 400 mg every 24 hours of moxifloxacin)
Number of subjects: 600
Study 22692171 — intervention group
Group type: COMPARATOR
Intervention: Meropenem alone
Number of subjects: 600
Study 22692171 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin and meropenem (combination therapy)
Number of subjects: 600
Study 22692171 — intervention group
Group type: COMPARATOR
Intervention: Meropenem alone (monotherapy)
Number of subjects: 600
Study 20808013 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infiltration of bupivacaine to the subcutaneous tissue and intra‐articular space for 48 hours, in addition to PCA
Number of subjects: 54
Study 20808013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐articular injection of local anaesthetic followed by continuous infiltration of bupivacaine to the subcutaneous tissue and intra‐articular space for 48 hours, in addition to PCA
Number of subjects: 54
Study 20808013 — intervention group
Group type: COMPARATOR
Intervention: Patient‐controlled analgesia (PCA) with intravenous morphine for 48 hours
Number of subjects: 54
Study 17682671 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 32
Study 17682671 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 32
Study 15063406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 192
Study 15063406 — intervention group
Group type: EXPERIMENTAL
Intervention: CMVIG
Number of subjects: 192
Study 15063406 — intervention group
Group type: COMPARATOR
Intervention: No anti-CMV therapy (Group 2)
Number of subjects: 192
Study 15063406 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (ganciclovir and CMVIG combined)
Number of subjects: 192
Study 15063406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 192
Study 15063406 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (no therapy)
Number of subjects: 192
Study 11140921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (up to 300 mg daily)
Number of subjects: 23
Study 11140921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11140921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 23
Study 9278797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diclofenac 0.1% and gentamicin 0.3% eyedrops (Digen)
Number of subjects: 90
Study 9278797 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 0.3% eyedrops
Number of subjects: 90
Study 7748321 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 8
Study 7748321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3729755 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride (Desyrel) 200 mg/d
Number of subjects: 27
Study 3729755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3729755 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride (Desyrel)
Number of subjects: 27
Study 30290289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 8246
Study 30290289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 8246
Study 30290289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8246
Study 27913929 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient multimodal pain therapy (MPT) with additional neuromuscular core stability exercises (NCSE), n = 25
Number of subjects: 48
Study 27913929 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC), n = 23
Number of subjects: 48
Study 25401406 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 31
Study 25401406 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 31
Study 23281263 — intervention group
Group type: COMPARATOR
Intervention: Standard OPEC/OJEC
Number of subjects: 262
Study 23281263 — intervention group
Group type: COMPARATOR
Intervention: Rapid COJEC
Number of subjects: 262
Study 23281263 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard OPEC/OJEC or Rapid COJEC
Number of subjects: 262
Study 21624672 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoButton
Number of subjects: 30
Study 21624672 — intervention group
Group type: COMPARATOR
Intervention: Transfix
Number of subjects: 30
Study 18289163 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of oral melatonin
Number of subjects: 46
Study 16611949 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 322
Study 16611949 — intervention group
Group type: COMPARATOR
Intervention: Control (no Burch colposuspension)
Number of subjects: 322
Study 12924757 — intervention group
Group type: EXPERIMENTAL
Intervention: EDH of 10,000 ft agl
Number of subjects: 30
Study 12924757 — intervention group
Group type: EXPERIMENTAL
Intervention: EDH of 6000 ft agl
Number of subjects: 30
Study 12924757 — intervention group
Group type: EXPERIMENTAL
Intervention: EDH of 3000 ft agl
Number of subjects: 30
Study 10871557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa beverage
Number of subjects: 30
Study 10871557 — intervention group
Group type: COMPARATOR
Intervention: Caffeine-containing beverage
Number of subjects: 30
Study 10871557 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 30
Study 9124665 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOTI device
Number of subjects: 50
Study 9124665 — intervention group
Group type: COMPARATOR
Intervention: Wee device
Number of subjects: 50
Study 8459063 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based bicycle exercise training
Number of subjects: 12
Study 8459063 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 12
Study 30957143 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic chronic liver disease cohort
Number of subjects: 17094
Study 30957143 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic liver disease with HBV or HCV cohort
Number of subjects: 17094
Study 29921381 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic discectomy (PTED)
Number of subjects: 216
Study 29921381 — intervention group
Group type: COMPARATOR
Intervention: Mini-incision surgery
Number of subjects: 216
Study 29921381 — intervention group
Group type: EXPERIMENTAL
Intervention: PTED
Number of subjects: 216
Study 27100415 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptic ulcer disease (PUD) group
Number of subjects: 27132
Study 27100415 — intervention group
Group type: COMPARATOR
Intervention: Non-PUD group (control)
Number of subjects: 27132
Study 27100415 — intervention group
Group type: EXPERIMENTAL
Intervention: PUD with proton-pump inhibitors (PPIs) use
Number of subjects: 27132
Study 27100415 — intervention group
Group type: COMPARATOR
Intervention: PUD group vs Non-PUD group
Number of subjects: 27132
Study 24150779 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12 240 mg twice daily (BID)
Number of subjects: 1237
Study 24150779 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12 240 mg three times daily (TID)
Number of subjects: 1237
Study 24150779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1237
Study 22007026 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial treatment (lifestyle and drug, including atorvastatin)
Number of subjects: 28
Study 22007026 — intervention group
Group type: COMPARATOR
Intervention: Control group (LDL-C target < 130 mg/dL)
Number of subjects: 28
Study 22007026 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial treatment
Number of subjects: 28
Study 22007026 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 20868531 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial adherence-based intervention (motivational interviews, pill reminders, family support, blood pressure self-recording, simplification of dosing regimen)
Number of subjects: 0
Study 20868531 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18604566 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal group therapy program (20 treatment days over 10 weeks)
Number of subjects: 24
Study 18604566 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (13 patients)
Number of subjects: 24
Study 15796645 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment with contingency management (CM) for 12 weeks
Number of subjects: 77
Study 15796645 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 77
Study 12452760 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 0
Study 10522578 — intervention group
Group type: EXPERIMENTAL
Intervention: mepivacaine 1% with 1 ml saline
Number of subjects: 152
Study 10522578 — intervention group
Group type: EXPERIMENTAL
Intervention: mepivacaine 1% with 5 ml saline
Number of subjects: 152
Study 10522578 — intervention group
Group type: EXPERIMENTAL
Intervention: mepivacaine 1% with 10 ml saline
Number of subjects: 152
Study 10522578 — intervention group
Group type: EXPERIMENTAL
Intervention: mepivacaine 1.5% with 1 ml saline
Number of subjects: 152
Study 10522578 — intervention group
Group type: EXPERIMENTAL
Intervention: mepivacaine 1.5% with 5 ml saline
Number of subjects: 152
Study 10522578 — intervention group
Group type: EXPERIMENTAL
Intervention: mepivacaine 1.5% with 10 ml saline
Number of subjects: 152
Study 8557965 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g elemental calcium given twice a day for 16 weeks)
Number of subjects: 32
Study 8557965 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 32
Study 8557965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1834592 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pantoprazole injected over 2 min on 5 consecutive days
Number of subjects: 8